Clin2
NCT07790445Possibly a fitNot yet recruiting

Adjuvant chemotherapy for bile duct cancer after surgery

Malignant Biliary Tract Tumors

Treatments studied

This study tests whether giving chemotherapy directly into the liver (HAIC) plus an oral chemo pill (capecitabine) after surgery helps prevent bile duct cancer from coming back, compared to just the pill. It's for people who recently had their cancer completely removed.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
90 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have been diagnosed with bile duct or gallbladder cancer that was completely removed by surgery
  • You have not had any other cancer treatments (like chemo, radiation, or immunotherapy) before or after your surgery
  • You are in good overall health (able to do daily activities)
  • Your blood counts and liver/kidney function are within acceptable levels
  • You agree to use birth control during the study and for 6 months after (if applicable)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07296666Not yet recruiting· Phase 2
Chemo after surgery for bile duct cancer

This trial tests a specific chemotherapy after surgery for people with stage II or III bile duct, gallbladder, or ampullary cancer. It may help reduce the chance of cancer coming back.

NCT06699459Not yet recruiting· Phase 2
Comparing two chemotherapies for bile duct cancer that returns after surgery

This trial compares two types of chemotherapy for people whose bile duct cancer has come back after surgery. It tests if a combination of irinotecan liposomes, 5-FU, and leucovorin works better than the standard pill capecitabine.

Fuzhou, Fujian
NCT06208462Recruiting· Phase 2
Combination therapy before surgery for high-risk bile duct cancer

This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.

Nanjing, Jiangsu
NCT06389500Not yet recruiting· Phase 2
HAIC plus immunotherapy and targeted therapy before surgery for bile duct cancer

This trial tests combining two drugs (adebrelimab and lenvatinib) with a liver-directed chemotherapy infusion (HAIC) to shrink locally advanced bile duct or gallbladder cancers enough to allow surgery. It is for people who haven't had prior treatment for their biliary cancer and whose cancer has not spread far.

NCT07636824Recruiting· Phase 2
Chemotherapy plus radiation after bile duct cancer surgery

This study tests whether combining chemotherapy and radiation therapy after surgery improves outcomes for patients with bile duct or gallbladder cancer. It's designed for patients whose surgery showed signs the cancer might come back.

Beijing
NCT06406816Recruiting· Early Phase 1
Vaccine and chemotherapy after surgery for bile duct cancer

This trial tests a personalized cancer vaccine combined with chemotherapy to help prevent bile duct cancer from coming back after surgery. It is for people who had their tumor removed but have a high risk of recurrence.

Fuzhou, Fujian

Hear when a new Malignant Biliary Tract Tumors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.